Author

Dr. Nathan Pryce

Dr. Nathan Pryce covers the biotech industry for Dark Biotechnology: companies, pipelines, financing and FDA decisions, with endpoint results and dollar figures carrying their disclosure basis.

Articles by Dr. Nathan Pryce

A researcher reviewing printouts of quarterly figures beside a laptop at a glass-walled laboratory office, cool daylight on brushed steel.

Biotech

How Biotech Earnings Season Actually Works for Industry Readers

Dr. Nathan Pryce

A scientist in safety glasses pipettes samples at a glass-and-steel bench, cool teal light and shallow depth of field.

Biotech

Anatomy of a Biotech Licensing Deal: Upfronts, Milestones and Tiered Royalties

Dr. Nathan Pryce

A gloved scientist loading assay plates under cool laboratory lighting, glass and steel surfaces reflecting teal.

Biotech

How Biomarkers and Companion Diagnostics Decide Who Gets Which Therapy

Dr. Nathan Pryce

A technician in full cleanroom gowning inspects a stainless-steel bioreactor vessel through glass, cool white and teal light, no logos.

Biotech

Biologics Manufacturing Explained: From Cell Bank to Vial

Dr. Nathan Pryce

A scientist studies a bar-chart readout on a monitor beside racked sample tubes, cool white and teal tones across a steel lab bench.

Biotech

How Biotech Financing Is Actually Structured, From Series A to IPO

Dr. Nathan Pryce

A gloved scientist reviews batch records beside stainless-steel bioreactor panels under cool white lab light.

Biotech

FDA Issues Complete Response Letter for Alvotech's Golimumab Biosimilar AVT05

Dr. Nathan Pryce